How blocking a specific protein may help treat colon cancer
Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer
This study is looking at a protein called claudin-1 that helps colon cancer spread, and it’s testing a new treatment that might make chemotherapy work better and stop the cancer from spreading further, all to help people with advanced colon cancer feel better and live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-11291157 on NIH RePORTER |
What this research studies
This research investigates the role of claudin-1, a protein that is linked to the spread of colon cancer, and how inhibiting it could reduce resistance to chemotherapy and metastasis. The study involves extensive laboratory work, including tests on cancer cell lines and mouse models, to evaluate the effectiveness of a newly developed small molecule inhibitor called PDS-0330. By understanding the mechanisms behind claudin-1's influence on cancer progression, the research aims to develop targeted therapies that could improve outcomes for patients with advanced colon cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colon cancer who are experiencing resistance to current chemotherapy treatments.
Not a fit: Patients with early-stage colon cancer or those who are not resistant to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the effectiveness of chemotherapy for colon cancer patients, particularly those with metastatic disease.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Dhawan, Punita — University of Kansas Medical Center
- Study coordinator: Dhawan, Punita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.